FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to genetic constructs containing microRNAs that are directed at inhibiting the CCR5 receptor gene, and having antiviral activity against the human immunodeficiency virus. Invention is a genetic construct for anti-HIV therapy that comprises a nucleotide sequence selected from SEQ ID NO 3 and SEQ ID NO 4.
EFFECT: invention allows to increase the effectiveness of anti-HIV therapy with this agent and to expand the arsenal of new generation antiviral drugs for treatment of HIV infection.
19 cl, 9 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVING GENETIC CONSTRUCTS FOR PROVIDING HIGH EFFICACY OF ANTI-HIV THERAPY | 2013 |
|
RU2533817C1 |
| GENETIC MAKE-UPS FOR ANTI-HIV THERAPY | 2010 |
|
RU2426788C1 |
| METHOD OF DETERMINING LEVEL OF CHIMERIC GENE Trim5a EXPRESSION | 2015 |
|
RU2592675C1 |
| METHODS OF OBTAINMENT AND APPLICATION OF MULTIPOTENT CELL POPULATIONS | 2008 |
|
RU2535365C2 |
| GENETIC CONSTRUCT FOR EXPRESSION OF mNG_CD4-CCR5 GENES, RECOMBINANT PLASMID rVSV_mNG_CD4-CCR5 AND RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS rVSV_mNG_CD4-CCR5 PROVIDING TARGETED VIROLYSIS OF CELLS DISPLAYING HIV-1 PROTEINS GP120/GP41 OF R5 TROPISM ON THEIR SURFACE | 2021 |
|
RU2769125C1 |
| GENETIC CONSTRUCT FOR GENE EXPRESSION mNG_CD4-CXCR4, RECOMBINANT PLASMID rVSV_MNG_CD4-CXCR4 AND A RECOMBINANT VESICULAR STOMATITIS VIRUS STRAIN rVSV_mNG_CD4-CXCR4, WHICH PROVIDES TARGETED VIROLYSIS OF CELLS EXPOSING HIV-1 GP120/GP41 PROTEINS TROPISM X4 ON THEIR SURFACE | 2021 |
|
RU2768032C1 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| COMPOSITIONS AND METHODS FOR TREATING HAEMOGLOBINOPATHIES | 2015 |
|
RU2707540C2 |
| MODIFICATION OF B-CELLS | 2018 |
|
RU2783116C2 |
| LENTIVIRAL VECTORS FOR PKLR DELIVERY FOR TREATMENT OF PYRUVATE KINASE DEFICIENCY | 2018 |
|
RU2777934C2 |
